Purpose: To examine the evidence on the cost-effectiveness of implementing pharmacogenomics (PGx) in cardiovascular disease (CVD) care. Methods: We conducted a systematic review using multiple databases from inception to 2018. The titles and abstracts of costeffectiveness studies on PGx-guided treatment in CVD care were screened, and full texts were extracted. Results: We screened 909 studies and included 46 to synthesize. Acute coronary syndrome and atrial fibrillation were the predominantly studied conditions (59%). Most studies (78%) examined warfarin-CYP2C9/VKORC1 or clopidogrel-CYP2C19. A payer's perspective was commonly used (39%) for cost calculations, and most studies (46%) were US-based. The majority (67%) of the studies found PGx testing to be cost-effective in CVD care, but costeffectiveness varied across drugs and conditions. Two studies examined PGx panel testing, of which one examined pre-emptive testing strategies. Conclusion: We found mixed evidence on the cost-effectiveness of PGx in CVD care. Supportive evidence exists for clopidogrel-CYP2C19 and warfarin-CYP2C9/VKORC1, but evidence is limited in other drug-gene combinations. Gaps persist, including unclear explanation of perspective and cost inputs, underreporting of study design elements critical to economic evaluations, and limited examination of PGx panel and pre-emptive testing for their costeffectiveness. This review identifies the need for further research on economic evaluations of PGx implementation.

We used data from the Nationwide Readmissions Database (NRD), 7 which is part of a family of databases and

Repeat hydrographic sections across the Antarctic Circumpolar Current (ACC) in Drake Passage are used to derive an empirical relationship between upper ocean temperature and the baroclinic transport stream function. Cross validation shows this relationship can be used to infer baroclinic transport (above and relative to 2500 m) from expendable bathythermograph (XBT) temperature measurements with an error of a few per cent. Transport errors of less than 2 Sv are obtained if temperature at depths between 600 and 1600 m is used to define the relationship. Temperature at depths above 300 m provides an unreliable index of transport because of variability in temperature‐salinity (T‐S) properties produced by air‐sea interaction. The scatter in the relationship between temperature and stream function from repeat observations along a single line is similar in magnitude to the scatter observed when data from the broader Drake Passage area are considered. In both cases, variability about the mean temperature‐stream function relationship reflects advection of water with anomalous T‐S properties. The tight relationship between temperature and stream function in Drake Passage and south of Australia suggests baroclinic transports can be inferred from XBT temperatures with high accuracy in the Southern Ocean, providing a cost‐effective means of monitoring ACC variability. However, care must be taken at the end points, particularly in the Drake Passage where the strong flow of the Subantarctic Front sometimes lies over the continental slope.

The Mayo Clinic Palliative Care Homebound Program reduced annual Medicare expenditures by $18,251 per program participant compared with matched control patients. This supports the role of home-based palliative medicine in delivering high-value care to high-risk older adults.

Importance:  This three-part study characterizes the widespread implementation of telehealth during the first year of the COVID-19 pandemic, giving us insight into the role of telehealth as we enter a stage of “new normal” healthcare delivery in the U.S. Objective: The COVID-19 Telehealth Impact Study was designed to describe the natural experiment of telehealth adoption during the pandemic.  Using a large claims data stream and surveys of providers and patients, we studied telehealth in all 50 states to inform healthcare leaders.  Design, Setting, Participants: In March 2020, the MITRE Corporation and Mayo Clinic founded the COVID-19 Healthcare Coalition (C19HCC), to respond to the pandemic. We report trends using a dataset of over 2 billion healthcare claims covering over 50% of private insurance activity in the U.S. (January 2019-December 2020), along with key elements from our provider survey (July-August 2020) and patient survey (November 2020 - February 2021). Main Outcomes and Measures: There was rapid and widespread adoption of telehealth in Spring 2020 with over 12 million telehealth claims in April 2020, accounting for 49.4% of total health care claims. Providers and patients expressed high levels of satisfaction with telehealth. 75% of providers indicated that telehealth enabled them to provide quality care.  84% of patients agreed that quality of their telehealth visit was good. Results: Peak levels of telehealth use varied widely among states ranging from 74.9% in Massachusetts to 25.4% in Mississippi.  Every clinical discipline saw a steep rise with the largest claims volume in behavioral health. Provision of care by out-of-state provider was common at 6.5% (October-December 2020). Providers reported multiple modalities of telehealth care delivery.  74% of patients indicated they will use telehealth services in the future. Conclusions and Relevance: Innovation shown by providers and patients during this period of rapid telehealth expansion constitutes a great natural experiment in care delivery with evidence supporting widespread clinical adoption and satisfaction on the part of both patients and clinicians. The authors encourage continued broad access to telehealth over the next 12 months to allow telehealth best practices to emerge, creating a more effective and resilient system of care delivery.